The European Union Drug Watch said on Thursday that it is assessing the possible use of Modern’s COVID-19 vaccine for children aged five and under, the only group not yet eligible for jab in most countries.
“We have just started the evaluation of an application by Moderna to extend the use of Spikevax to children from the age of six months to five years,” said Marco Cavaleri, Head of Anti-Infection and Vaccines at the European Medicines Agency (EMA). .
“This is the first application for this young age group,” Cavaleri said.
In February, the EMA’s Human Medicine Committee had already recommended giving an extension of the indication for the Spikevax vaccine Spikevax to include use in children aged six to 11 years.
The jab, developed by US-based Moderna, had already been approved for adults and children aged 12 and over.
The Amsterdam-based EMA has so far approved five vaccines for use in the EU: Pfizer and Moderna, which use messenger RNA technology, AstraZeneca and Johnson & Johnson, which uses viral vector technology, and Novavax, which is based on a nail protein produced. in a laboratory.